The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric Cancer
Overview
Affiliations
Gastric cancer is one of the leading causes of cancer deaths worldwide, with chronic gastritis representing the main predisposing factor initiating the cascade of events leading to metaplasia and eventually progressing to cancer. A widely accepted classification distinguishes between autoimmune and environmental atrophic gastritis, mediated, respectively, by T cells promoting the destruction of the oxyntic mucosa, and chronic infection, which has also been identified as the major risk factor for gastric cancer. The original dogma posits Th1 immunity as a main causal factor for developing gastritis and metaplasia. Recently, however, it has become evident that Th2 immune responses play a major role in the events causing chronic inflammation leading to tumorigenesis, and in this context, many different cell types and cytokines are involved. In particular, the activity of cytokines, such as IL-33 and IL-13, and cell types, such as mast cells, M2 macrophages and eosinophils, are intertwined in the process, promoting chronic gastritis-dependent and more diffuse metaplasia. Herein, we provide an overview of the critical events driving the pathology of this disease, focusing on the most recent findings regarding the importance of Th2 immunity in gastritis and gastric metaplasia.
in the development and treatment of precancerous lesions of gastric cancer.
Qian S, Zhao H, Xie F, Liu Q, Cai D World J Gastrointest Oncol. 2024; 16(9):3771-3780.
PMID: 39350992 PMC: 11438778. DOI: 10.4251/wjgo.v16.i9.3771.
Pro- and anti-inflammatory cytokines: the hidden keys to autoimmune gastritis therapy.
Cascetta G, Colombo G, Eremita G, Garcia J, Lenti M, Di Sabatino A Front Pharmacol. 2024; 15:1450558.
PMID: 39193325 PMC: 11347309. DOI: 10.3389/fphar.2024.1450558.
Considerations on the evolutionary biology and functions of eosinophils: what the "haeckel"?.
Ackerman S, Stacy N J Leukoc Biol. 2024; 116(2):247-259.
PMID: 38736141 PMC: 11288384. DOI: 10.1093/jleuko/qiae109.
Prognosis and Treatment of Gastric Cancer: A 2024 Update.
Burz C, Pop V, Silaghi C, Lupan I, Samasca G Cancers (Basel). 2024; 16(9).
PMID: 38730659 PMC: 11083929. DOI: 10.3390/cancers16091708.